1. Rescue renal sympathetic denervation in a patient with ventricular electrical storm refractory to endo- and epicardial catheter ablation: response to comments by Huang et al.

    Clinical Research in Cardiology 104(2):194 (2015) PMID 25315044

  2. Rescue renal sympathetic denervation in a patient with ventricular electrical storm refractory to endo- and epicardial catheter ablation.

    Clinical Research in Cardiology 104(1):79 (2015) PMID 25098585

  3. IL-17A influences essential functions of the monocyte/macrophage lineage and is involved in advanced murine and human atherosclerosis.

    Journal of Immunology 193(9):4344 (2014) PMID 25261478 PMCID PMC4201987

    Atherosclerosis is a chronic inflammatory disease. Lesion progression is primarily mediated by cells of the monocyte/macrophage lineage. IL-17A is a proinflammatory cytokine, which modulates immune cell trafficking and is involved inflammation in (auto)immune and infectious diseases. But the rol...
  4. IL-17A influences essential functions of the monocyte/macrophage lineage and is involved in advanced murine and human atherosclerosis.

    Journal of Immunology 193(9):4344 (2014) PMID 25261478 PMCID PMC4201987

    Atherosclerosis is a chronic inflammatory disease. Lesion progression is primarily mediated by cells of the monocyte/macrophage lineage. IL-17A is a proinflammatory cytokine, which modulates immune cell trafficking and is involved inflammation in (auto)immune and infectious diseases. But the rol...
  5. Response to letter regarding article, "ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension".

    Circulation 129(20):e500 (2014) PMID 24842939

  6. MiRNAs in peripheral artery disease - something gripping this way comes.

    Vasa 43(3):163 (2014) PMID 24797047

    Peripheral artery disease (PAD) is a marker disease for generalized atherosclerosis and represents one of the world's major causes of morbidity and mortality. Many studies have tried to gain insight into the molecular mechanisms involved in PAD onset, progression and prognosis. In the last decad...
  7. Renal sympathetic denervation therapy in the real world: results from the Heidelberg registry.

    Clinical Research in Cardiology 103(2):117 (2014) PMID 24126436

    Renal sympathetic denervation (RDN) is a novel treatment option in patients with treatment-resistant arterial hypertension. A subset of recently published randomized and non-randomized trials indicates that RDN leads to sustained lowering of blood pressure (BP) under controlled study conditions....
  8. Randomized, controlled trial of ultrasound-assisted catheter-directed thrombolysis for acute intermediate-risk pulmonary embolism.

    Circulation 129(4):479 (2014) PMID 24226805

    In patients with acute pulmonary embolism, systemic thrombolysis improves right ventricular (RV) dilatation, is associated with major bleeding, and is withheld in many patients at risk. This multicenter randomized, controlled trial investigated whether ultrasound-assisted catheter-directed throm...
  9. Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension.

    Circulation 128(2):132 (2013) PMID 23780578

    Catheter-based renal sympathetic denervation (RDN) reduces office blood pressure (BP) in patients with resistant hypertension according to office BP. Less is known about the effect of RDN on 24-hour BP measured by ambulatory BP monitoring and correlates of response in individuals with true or ps...
  10. Stent placement versus balloon angioplasty for the treatment of obstructive lesions of the popliteal artery: a prospective, multicenter, randomized trial.

    Circulation 127(25):2535 (2013) PMID 23694965

    Stenting has been shown to improve patency after femoral artery revascularization compared with balloon angioplasty. Limited data are available evaluating endovascular treatment for obstructive lesions of the popliteal artery. This prospective, randomized, multicenter trial compared primary niti...
  11. Renal denervation: tips and tricks to perform a technically successful procedure.

    EuroIntervention 9 Suppl R:R83 (2013) PMID 23732161

    To most practitioners involved in catheter-based interventions, percutaneous renal sympathetic denervation is not technically challenging. However, under specific clinical circumstances (e.g., renal insufficiency) or when faced with more complex abdominal aortic anatomy (e.g., tortuosity) some p...
  12. Cardiac Ablation and Renal Denervation Systems Have Distinct Purposes and Different Technical Requirements

    JACC: Cardiovascular Interventions 6(3):314 (2013)

  13. Cardiac ablation and renal denervation systems have distinct purposes and different technical requirements.

    Journal of the American College of Cardiology: ... 6(3):314 (2013) PMID 23517846

  14. GDF-15 protects from macrophage accumulation in a mousemodel of advanced atherosclerosis.

    European journal of medical research 18:19 (2013) PMID 23800095 PMCID PMC3701574

    The cytokine growth differentiation factor-15 (GDF-15), a member of the TGF beta superfamily, has recently been discovered to play an important role in cardiovascular diseases. It is mostly expressed in macrophages of atherosclerotic lesions, but its impact on advanced atherosclerosis is still u...
  15. TCT-208 Catheter-based renal sympathetic denervation – results of the heidelberg registry

    Journal of the American College of Cardiology 60(17):B61 (2012)

  16. Minocycline reduces plaque size in diet induced atherosclerosis via p27(Kip1).

    Atherosclerosis 219(1):74 (2011) PMID 21719015

    Minocycline, a tetracycline derivate, mediates vasculoprotective effects independent of its antimicrobial properties. Thus, minocycline protects against diabetic nephropathy and reduces neointima formation following vascular injury through inhibition of apoptosis or migration, respectively. Whet...
  17. Minocycline reduces plaque size in diet induced atherosclerosis via p27(Kip1).

    Atherosclerosis 219(1):74 (2011) PMID 21719015

    Minocycline, a tetracycline derivate, mediates vasculoprotective effects independent of its antimicrobial properties. Thus, minocycline protects against diabetic nephropathy and reduces neointima formation following vascular injury through inhibition of apoptosis or migration, respectively. Whet...
  18. Deletion of bone marrow-derived receptor for advanced glycation end products inhibits atherosclerotic plaque progression.

    European Journal of Clinical Investigation 41(11):1164 (2011) PMID 21418204

    The multiligand receptor for advanced glycation end products (RAGE) of the immunoglobulin superfamily is expressed on multiple cell types implicated in the inflammatory response in atherosclerosis. We sought to determine the role of bone marrow-derived RAGE in different stages of atherosclerotic...
  19. Nicotinic acid has anti-atherogenic and anti-inflammatory properties on advanced atherosclerotic lesions independent of its lipid-modifying capabilities.

    Journal of Cardiovascular Pharmacology 57(4):447 (2011) PMID 21242806

    Inflammation contributes to atherosclerotic plaque initiation and progression. Recent studies suggest that nicotinic acid has anti-inflammatory effects independent of its lipid-modifying capabilities. We assessed the hypothesis that administration of nicotinic acid to older apolipoprotein E (apo...
  20. Minocycline reduces plaque size in diet induced atherosclerosis via p27Kip1

    Atherosclerosis 219(1):74 (2011)

    Highlights ► Minocycline is a widely used tetracycline derivate with off-target effects. ► The effect of minocycline on de novo atherogenesis remains unknown. ► Minocycline reduces plaque size and vascular stenosis in ApoE−/− mice receiving a high fat diet. ► Minocycline inhibits proli...